Biomarkers /
XRCC4
Overview
XRCC4 is altered in 0.74% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, glioblastoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in XRCC4 are XRCC4 Mutation (0.67%), XRCC4 Loss (0.03%), XRCC4 S260I (0.03%), XRCC4 A249G (0.03%), and XRCC4 P119T (0.02%) [3].
Clinical Trials
Significance of XRCC4 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.